Sequential combination therapy with prednisone, lamivudine and interferon alfa-2b for HBeAg-positive chronic hepatitis B;Terapia de combinación secuencial con prednisona, lamivudina e interferón alfa-2b en pacientes con hepatitis crónica B y antígeno e positivo

Gastroenterologia y Hepatologia

Volumn 29, Issue 9, 2006, Pages 534-541

  Vilar Gómez, Eduardo ^a   Oramas, Blenvenido Grá ^a   Soler, Enrique Arús ^a   Domech, Caridad Ruenes ^a   González, Yudith Dávila ^a  

^a INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PREDNISONE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FIBROSIS; HEPATITIS B; HISTOPATHOLOGY; HUMAN; INFLAMMATION; MULTIPLE CYCLE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

EID: 33845382362     PISSN: 02105705     EISSN: None     Source Type: Journal    
DOI: 10.1157/13094348     Document Type: Article

References (28)

1. Conjeevaram HS, Lok AS-F. Management of chronic hepatitis B. J Hepatol. 2003;38:90S-103S.
2. Lai CL, Ratziu V, Yuen M-F, Poynard T. Viral hepatitis B. Lancet. 2003;362:2089-94.
3. Lok ASF, McMahon BJ. AASLD practice guideline: chronic hepatitis B update of recommendations. Hepatology. 2004;39:857-61.
4. Liaw YF. Results of lamivudine in Asian trials. J Hepatol. 2003;39:125S-9S.
5. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. N Engl J Med. 2003;348:808-16.
6. Schalm SW. Combination therapy for chronic hepatitis B. J Hepatol. 2003;39:146S-50S.
7. Cohard M, Poynard T, Mathurin P, et al. Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect meta-analysis. Hepatology. 1994;20:1390-8.
8. Liaw YF, Tsai SL, Chien RN, et al. Prednisolone priming enhances Th 1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology. 2002;32:604-9.
9. Perrillo RP, Schiff ER, Davis GL, et al. A ramdomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295-301
10. Common toxicity criteria, version 2. Bethesda. National Cancer Institute, 1999 [citado 15 Dic 2004]. Disponible en: http://ctep.info.nih.gov
11. The EASL Jury. EASL international consensus conference on hepatitis B. Consensus statement (Short version). J Hepatol. 2003;38:533-40.
12. Cooksley WGE, Piratvisuth T, Wang YJ, et al. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatitis. 2003;10:298-305.
13. Marcellin P, Lau GK, Bonino F, et al. A phase III, partially double-blind study evaluating the efficacy and safety of peginterferon alfa-2a (40 kD) alone or in combination with lamivudine vs lamivudine in 537 patients with HBeAg-negative/anti-HBe-positive chronic hepatitis B. Programs and abstracts from the 55th Annual Meeting of the American Association for the Study of the Liver Diseases. Boston (Massachusetts), del 29 de octubre al 2 de noviembre de 2004.
14. Krogsgaard K. Does corticosteroid pretreatment enhance the effect of alpha interferon treatment in chronic hepatitis B. J Hepatol. 1994;20:159-62.
15. Krogsgaard K, Marcellin P, Trepo C, et al. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. J Hepatol. 1996;25:803-13.
16. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminasa level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology. 1999;30:770-4.
17. Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhaces durability of Lamivudine-induced HBeAg loss: a prospective study. J Hepatol. 2003;39:614-9.
18. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46:562-8.
19. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003;38:818-26.
20. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter randomized trial. J Hepatol. 2001;35:406-11.
21. Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B: a controlled pilot study. J Hepatol. 2002;36:799-804.
22. Liaw YF, Liu SM, Chang TJ, et al. Beneficial effect of prednisolone withdrawal followed by lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomized controlled trial. Hepatology. 1994;20:175-80.
23. Chau CK. Wang LH, Lim HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992;16:13-8.
24. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid: responsive element. Proc Natl Acad Sci USA. 1986;83:1627-31.
25. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-74.
26. Lai CL, Chien RN, Leung NYW, et al. A one-year trial of lamivudine of chronic hepatitis B. N Engl J Med. 1998;339:61-8.
27. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in United States. N Engl J Med. 1999;341:1256-63.
28. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696-9.